Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.vaccine.2009.11.054
Title: Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children
Authors: Lum, L.C.S.
Borja-Tabora, C.F.
Breiman, R.F.
Brooks, W.A.
Vesikari, T.
Sablan, B.P.
Chay, O.M.
Tantracheewathorn, T.
Schmitt, H.-J.
Lau, Y.-L.
Bowonkiratikachorn, P.
Tam, J.S.
Lee, B.W. 
Tan, K.K.
Pejcz, J.
Cha, S.
Gutierrez-Brito, M.
Kaltenis, P.
Vertruyen, A.
Czajka, H.
Bojarskas, J.
Cheng, S.-M.
Rappaport, R.
Baker, S.
Gruber, W.C.
Forrest, B.D.
Keywords: Combined vaccines
Live attenuated influenza vaccine
Measles-mumps-rubella vaccine
Vaccine interference
Issue Date: 2010
Citation: Lum, L.C.S., Borja-Tabora, C.F., Breiman, R.F., Brooks, W.A., Vesikari, T., Sablan, B.P., Chay, O.M., Tantracheewathorn, T., Schmitt, H.-J., Lau, Y.-L., Bowonkiratikachorn, P., Tam, J.S., Lee, B.W., Tan, K.K., Pejcz, J., Cha, S., Gutierrez-Brito, M., Kaltenis, P., Vertruyen, A., Czajka, H., Bojarskas, J., Cheng, S.-M., Rappaport, R., Baker, S., Gruber, W.C., Forrest, B.D. (2010). Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 28 (6) : 1566-1574. ScholarBank@NUS Repository. https://doi.org/10.1016/j.vaccine.2009.11.054
Abstract: Children aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35 ± 7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV + Priorix recipients were statistically lower at a 15 IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10 IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the overall influenza protection rate of LAIV (78.4% and 63.8% against antigenically similar influenza strains and any strain, respectively). © 2009 Elsevier Ltd. All rights reserved.
Source Title: Vaccine
URI: http://scholarbank.nus.edu.sg/handle/10635/25664
ISSN: 0264410X
DOI: 10.1016/j.vaccine.2009.11.054
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.